ANAB Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 114544 min ago

@ $22.40

Wydano: 13 vas. 2024 @ 16:30

Zwrot: 17.59%

Poprzedni sygnał: vas. 12 - 16:36

Poprzedni sygnał: Sprzedaż

Zwrot: -3.80 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications...

Stats
Dzisiejszy wolumen	317 726
Średni wolumen	361 357
Kapitalizacja rynkowa	719.57M
EPS	$0 ( 2024-03-13 )
Następna data zysków	( $-1.540 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.33
ATR14	$0.0430 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-22	Faga Daniel	Sell	145 940	Common Stock
2024-03-25	Faga Daniel	Sell	3 000	Common Stock
2024-03-26	Faga Daniel	Sell	347 441	Common Stock
2024-02-16	Loumeau Eric J	Sell	5 000	Employee Stock Option (right to buy)
2024-02-16	Loumeau Eric J	Buy	5 000	Common Stock

INSIDER POWER
37.29
Last 98 transactions
Buy: 3 215 504 \| Sell: 1 263 529

Wolumen Korelacja

Długi: -0.17 (neutral)

Krótki: -0.91 (very strong negative)

Signal:(25.755) Possible Trading Opportunity Present (swing)

AnaptysBio Inc Korelacja

10 Najbardziej pozytywne korelacje
CDXS	0.959
TRIP	0.957
ZD	0.956
SRTS	0.954
CSGS	0.953
ETSY	0.95
LGHL	0.944
HNNA	0.941
NMTR	0.94
VERI	0.94

10 Najbardziej negatywne korelacje
MSDA	-0.938
DHAC	-0.929
MCAA	-0.928
MYRG	-0.92
BRIV	-0.918
RELY	-0.917
SKYA	-0.917
BRIVU	-0.916
FICV	-0.914
ADAL	-0.914

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AnaptysBio Inc Korelacja - Waluta/Towar

-0.04
( neutral )

0.03
( neutral )

0.00
( neutral )

-0.39
( neutral )

0.49
( neutral )

-0.23
( neutral )

AnaptysBio Inc Finanse

Annual	2023
Przychody:	$17.16M
Zysk brutto:	$14.78M (86.15 %)
EPS:	$-6.08

FY	2023
Przychody:	$17.16M
Zysk brutto:	$14.78M (86.15 %)
EPS:	$-6.08

FY	2022
Przychody:	$10.29M
Zysk brutto:	$7.95M (77.30 %)
EPS:	$-4.57

FY	2021
Przychody:	$63.18M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.11

Financial Reports:

No articles found.

AnaptysBio Inc

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.